Ofev (nintedanib) is safe and effective for adults with idiopathic pulmonary fibrosis…
Steve Bryson, PhD
Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Steve Bryson, PhD
Japanese people diagnosed with both pulmonary fibrosis (PF) and emphysema…
Adelmidrol therapy reduced markers for inflammation and oxidative stress, as well as tissue damage and…
Blocking an enzyme — called 15-PGDH — in a mouse model of pulmonary fibrosis…
The protective tips of chromosomes, called telomeres, are shorter in men with idiopathic pulmonary…
Rates of hospitalization and in-hospital mortality dropped significantly for people with idiopathic pulmonary fibrosis (IPF) in the…
Treating acute exacerbations with the protein thrombomodulin (ART-123) in idiopathic pulmonary fibrosis (IPF) patients may be associated…
Low levels of a protein called esRAGE, present in the blood and lungs of people with…
Survival chances for people with an acute exacerbation linked to idiopathic pulmonary fibrosis (IPF)…
Ofev, an approved treatment of idiopathic pulmonary fibrosis (IPF), may…